Pathological Margin Clearance and Survival After Pancreaticoduodenectomy in a US and European Pancreatic Center by van Roessel, Stijn et al.
Pathological Margin Clearance and
Survival After Pancreaticoduodenectomy
in a US and European Pancreatic Center
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation van Roessel, S., G. G. Kasumova, O. Tabatabaie, S. C. Ng, L. B.
van Rijssen, J. Verheij, R. M. Najarian, et al. 2018. “Pathological
Margin Clearance and Survival After Pancreaticoduodenectomy
in a US and European Pancreatic Center.” Annals of Surgical
Oncology 25 (6): 1760-1767. doi:10.1245/s10434-018-6467-9. http://
dx.doi.org/10.1245/s10434-018-6467-9.
Published Version doi:10.1245/s10434-018-6467-9
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160049
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
ORIGINAL ARTICLE – PANCREATIC TUMORS
Pathological Margin Clearance and Survival After
Pancreaticoduodenectomy in a US and European Pancreatic
Center
Stijn van Roessel, MD1,2, Gyulnara G. Kasumova, MD1, Omidreza Tabatabaie, MD, MPH1, Sing Chau Ng, MS1,5,
L. Bengt van Rijssen, MD2, Joanne Verheij, MD, PhD3, Robert M. Najarian, MD4, Thomas M. van Gulik, MD,
PhD2, Marc G. Besselink, MD, MSc, PhD2, Olivier R. Busch, MD, PhD2, and Jennifer F. Tseng, MD, MPH1,5
1Surgical Outcomes Analysis & Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;
2Department of Surgery, Cancer Center Amsterdam, Academic Medical Center Amsterdam, Amsterdam, The Netherlands;
3Department of Pathology, Cancer Center Amsterdam, Academic Medical Center Amsterdam, Amsterdam, The
Netherlands; 4Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA;
5Department of Surgery, Boston Medical Center, Boston University School of Medicine, Boston, MA
ABSTRACT
Background. The optimal definition of a margin-negative
resection and its exact prognostic significance on survival
in resected pancreatic adenocarcinoma remains unknown.
This study was designed to assess the relationship between
pathological margin clearance, margin type, and survival.
Methods. Patients who underwent pancreaticoduodenec-
tomy with curative intent at two academic institutions, in
Amsterdam, the Netherlands, and Boston, Massachusetts,
between 2000 and 2014 were retrospectively evaluated.
Overall survival, recurrence rates, and progression-free
survival (PFS) were assessed by Kaplan–Meier estimates
and multivariate Cox proportional hazards analysis,
according to pathological margin clearance and type of
margin involved.
Results. Of 531 patients identified, the median PFS was
12.9, 15.4, and 24.1 months, and the median overall sur-
vival was 17.4, 22.9, and 27.7 months for margin
clearances of 0,\ 1, and C1 mm, respectively (all log-
rank p\ 0.001). On multivariate analysis, patients with a
margin clearance of C1 mm demonstrated a survival
advantage relative to those with 0 mm clearance [hazard
ratio (HR) 0.71, p\ 0.01], whereas survival was compa-
rable for patients with a margin clearance of\ 1 mm
versus 0 mm (HR: 0.93, p = 0.60). Patients with involve-
ment (0 or\ 1 mm margin clearance) of the SMV/PV
margin demonstrated prolonged median overall survival
(25.7 months) relative to those with SMA involvement
(17.5 months).
Conclusions. In patients undergoing pancreaticoduo-
denectomy for pancreatic adenocarcinoma, a margin
clearance of C1 mm correlates with improved survival
relative to\ 1 mm clearance and may be a more accurate
predictor of a complete margin-negative resection in pan-
creatic cancer. The type of margin involved also appears to
impact survival.
Pancreatic cancer is currently the third-leading cause of
cancer-related mortality in the United States with an esti-
mated annual incidence of 16.5 per 100,000 individuals in
2017 and an annual mortality of 13.3 per 100,000.1 Surgery
combined with adjuvant therapy offers the best chance for
long-term survival, but even the minority of patients with
localized disease amenable to curative-intent resection face
a 5-year survival that rarely exceeds 20–25%.2–4 Resection
margin status is a key prognosticator after surgery and
often is used to stratify patients enrolled in clinical trials of
adjuvant therapy.2,5 However, controversy exists as several
studies have failed to demonstrate a survival benefit for
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patients with a margin-negative resection.6–8 The exact
prognostic significance of margin involvement remains
fairly understudied in the current literature.
Rates of microscopically positive resection margins
(R1) and local recurrence vary widely in the literature,
contributing to the unclear relationship between margin
status and survival.6,9–11 Traditionally, the proportion of
margin-negative resections has been recognized as an
indicator of surgical quality; however, some argue that high
R1 rates may be considered a reflection of high-quality
pathological assessment, rather than inadequate surgical
technique.12,13 Microscopically negative resection margins
typically refers to the absence of tumor cells at the inked
resection margin (margin clearance[ 0 mm) according to
College of American Pathologists (CAP), but many Euro-
pean centers define a margin-negative resection as no
tumor cells within 1 mm of the resection margin, according
to the UK Royal College of Pathologists (RCPath).14,15
Inconsistency persists in the definitions and protocols used
with potentially crucial consequences for the generaliz-
ability of outcomes of currently ongoing randomized,
controlled trials on resected pancreatic cancer.16
The present study was designed to elucidate the rela-
tionship between pathological margin clearance and
outcomes after pancreaticoduodenectomy (PD) for pan-
creatic ductal adenocarcinoma in a multicenter cohort from
the Netherlands and the United States to establish a clini-
cally meaningful R1 definition which best correlates with
survival. Additionally, the prognostic significance of vari-
ous resection margins on clinical outcome are evaluated.
METHODS
Data Collection
Patients who underwent PD between 2000 and 2014 at
Academic Medical Center, Amsterdam, the Netherlands
(AMC) and between 2001 and 2014 at Beth Israel Dea-
coness Medical Center, Boston, Massachusetts (BID) were
retrospectively identified from prospectively maintained
institutional databases. Only patients with a histopathologic
diagnosis of pancreatic ductal adenocarcinoma (histology
ICD-O-3 codes 8140 and 8500) were included. Patients
who received neoadjuvant therapy, had metastatic disease,
or grossly positive resection margins (R2 resections) were
excluded. All pathology reports were reviewed, and addi-
tional data on margin clearance and the specific margins
involved were extracted. Ambiguities in the pathology
report were resolved in consultation with a senior pancre-
atic pathologist at each institution (J.V. and R.M.N.) and
specimens were retrospectively reevaluated, if necessary.
Pathological Assessment
The resection margins were postoperatively either
marked by the surgeon and inked by the pathologist or
immediately inked by the surgeon, followed by fixation of
the specimen in formalin. Throughout the study period,
different grossing techniques for margin assessment were
used at both institutions, including the protocols previously
described by Adsay and Verbeke.17,18 The routinely eval-
uated margins with all grossing protocols used included the
pancreatic neck margin, the superior mesenteric artery
(SMA)/uncinate margin, the superior mesenteric vein
(SMV)/portal vein (PV) margin, the enteric margins, and
the bile duct margin. The posterior retroperitoneal/radial
margin was routinely assessed at BID, but not until 2009 at
AMC. The examination of the anterior margin gradually
became part of the routine margin assessment over time at
both institutions.
Margin clearance was defined as the distance from the
tumor to the nearest resection margin and reported in
millimeters (mm). Because the pancreatic neck margin was
sectioned and examined parallel to this resection margin
(en face), measuring the exact margin clearance was not
possible at either institution. Instead, only a determination
of involvement or uninvolvement by tumor was recorded
for this margin. All other margins were assessed perpen-
dicularly, allowing the pathologist to define margin
clearance of 0 mm (tumor cells at inked margin),\ 1 mm
(tumor cells[ 0 mm but\ 1 mm from margin) or C1 mm
(tumor cells C 1 mm from margin). At BID, the margins
were assessed without shaving them off the specimen,
enabling the pathologist to differentiate margin clearances
beyond 1 mm (i.e., 1–2 mm vs.[ 2 mm). Tumors were
pathologically staged according to the American Joint
Committee on Cancer (AJCC) 7th edition.19 In the analysis
of various positive resection margins, we considered a
margin clearance of less than 1 mm as margin-positive
(RCPath definition) to ensure consistency within the entire
cohort. Patients with a margin clearance of C1 mm were
considered as margin-negative, including patients with
stated negative margins in the pathology report but missing
reported margin clearances (n = 12).
Statistical Analysis
SAS software version 9.4 (SAS Institute, Cary, NC) was
used for all statistical analyses. Clinical and pathological
characteristics were compared using Chi square, or Fisher’s
exact test if any cell frequencies were\ 5. Numeric data
were presented as medians and interquartile ranges (IQR).
The primary outcome was overall survival, calculated as
the time in months between date of surgery and date of
death, or censored at the date of last follow-up. Survival
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was assessed using the Kaplan–Meier method and log-rank
tests. Additional endpoints included progression-free sur-
vival, where recurrence was defined as radiographic or
pathological evidence of disease progression. The site of
recurrence was also collected, including recurrence in the
resection bed (local recurrence), in the liver and lung, or a
combination (local and distant recurrence). Patients with an
isolated positive pancreatic neck margin were excluded
(n = 27) from the analysis of margin clearance due to the
parallel margin assessment.
Multivariate analysis was performed using a Cox pro-
portional hazards model. All patients with one or more
missing variables were excluded from multivariate analysis
(n = 22), as were those with an isolated positive pancreatic
neck margin (n = 27). A subset analysis of the BID cohort
was performed, because further differentiation of margin
clearance was possible (i.e., 1–2 mm and[ 2 mm) due to
the margin assessment technique. Variables that violated
the proportional hazard assumption were accounted for by
stratification. A two-tailed p\ 0.05 was considered sta-
tistically significant.
This study was approved by the Institutional Review
Boards of both institutions. Study data were collected and
managed using the REDCap (Research Electronic Data
Capture) electronic data capture tools hosted at BID.20
RESULTS
Characteristics and Outcomes of the Initial Cohort
The final cohort comprised 531 patients, of whom 255
(48.0%) and 276 (52.0%) underwent PD at AMC and BID,
respectively. Baseline demographics and clinicopathologi-
cal characteristics are shown in Table 1. Median age was
66 years [interquartile (IQR) 59–73], and 51.8% of the
patients were male. Cohorts of both institutions were
comparable in terms of age, sex, and the proportion with
positive lymph nodes. In addition to other baseline differ-
ences, a higher proportion of the patients treated at BID
received adjuvant therapy (70.6% vs. 54.9%), and they
were more likely to receive radiotherapy in addition to
chemotherapy compared with those treated at AMC (49.6%
vs. 4.3%). The 90-day mortality was 2.8% and 1.1%
(p = 0.21), and the median overall survival was 23.6 and
23.5 months (p = 0.34) for patients treated at AMC and
BID, respectively. The median follow-up time was
49.9 months (IQR 32.3–81.5) for survivors.
Survival Outcomes by Margin Clearance
For patients with a margin clearance of 0 mm,\ 1 mm,
and C1 mm, the median overall survival was 17.4, 22.9,
and 27.7 months (p\ 0.001), and the 5-year survival rate
was 16.3, 12.4, and 27.6%, respectively (Fig. 1). Survival
was improved in patients with a margin clearance of
C1 mm relative to those with a clearance of 0 mm
(p\ 0.001) and\ 1 mm (p = 0.02), whereas there was no
significant difference in survival between patients who had
a margin clearance of 0 mm versus\ 1 mm (p = 0.60) on
unadjusted analysis. Similarly, recurrence data demon-
strated a median PFS of 12.9 and 15.4 months for 0
and\ 1 mm margin clearance (p = 0.48), whereas patients
with a margin clearance of C1 mm showed a prolonged
median PFS (24.1 months) compared with 0 mm
(p = 0.001) and\ 1 mm (p\ 0.001). PFS by margin
clearance and patterns of recurrence are depicted in the
supplementary material (Figs. S1 and S2).
On multivariate analysis a higher ASA score, positive
lymph nodes, and poorly/undifferentiated tumors were
associated with a significantly increased hazard ratio
(Fig. 2). Patients with a margin clearance of C1 mm
demonstrated a survival advantage versus 0 mm (HR 0.71,
p\ 0.01), whereas patients with a margin clearance of
\ 1 mm did not demonstrate a survival benefit versus
0 mm (HR 0.93, p = 0.60). In the subset analysis of
patients treated at BID, there was a trend towards a
decreased hazard ratio for patients with both a margin
clearance of 1–2 mm (HR 0.65, p = 0.05), as well as[ 2
mm (HR 0.67, p = 0.07) compared with the 0 mm clear-
ance group (Fig. 3).
Survival Outcomes by Positive Margins
Using the definition of\ 1 mm to define a positive
margin (RCPath definition), 257 patients (48.4%) of the
entire cohort had defined margin involvement. The most
commonly involved margins were the SMA margin
(n = 113, 43.6% of all patients with a margin clearance
of\ 1 mm), the SMV/PV margin (n = 77, 29.7%) and the
posterior retroperitoneal margin (n = 75, 29.0%), which
also were associated with the highest 1-year local recur-
rence rate (32.0% for the SMA margin, 32.2% for the
SMV/PV margin, and 38.4% for the posterior retroperi-
toneal margin) as shown in Table 2. Patients with a
positive SMV/PV margin had a significantly prolonged
survival, particularly the subgroup not requiring venous
resection (26.3 months, p = 0.03), compared with patients
with one or more other positive margins (\ 1 mm),
whereas patients with a positive SMA margin had a trend
towards worse survival (17.5 months).
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TABLE 1 Baseline characteristics of the initial cohort by institution
AMC (n = 255) BID (n = 276) p value
Age (year)
\ 65 115 (45.1%) 117 (42.4%) 0.53
C 65 140 (54.9%) 159 (57.6%)
Sex
Male 135 (52.9%) 140 (50.7%) 0.61
Female 120 (47.1%) 136 (49.3%)
ASA score
ASA I 50 (19.6%) 0 (0%) \ 0.0001
ASA II 150 (58.8%) 92 (33.3%)
ASA III 39 (15.3%) 175 (63.4%)
ASA IV 16 (6.3%) 9 (3.3%)
Type surgery
PPPD 218 (85.5%) 28 (10.1%) \ 0.0001
Whipple 37 (14.5%) 248 (89.9%)
Vascular resection
Yes 53 (20.8%) 24 (8.7%) \ 0.0001
No 202 (79.2%) 252 (91.3%)
Adjuvant therapy
Chemoradiation 11 (4.3%) 137 (49.6%) \ 0.0001
Only chemotherapy 129 (50.6%) 52 (18.8%)
Only radiotherapy 0 (0%) 6 (2.2%)
No adjuvant therapy 112 (43.9%) 81 (29.3%)
Unknown 3 (1.2%) 0 (0%)
AJCC T stage
T1 17 (6.7%) 22 (8.0%) 0.02
T2 54 (21.2%) 34 (12.3%)
T3/T4 184 (72.2%) 220 (79.7%)
AJCC N stage
N0 54 (21.2%) 77 (27.9%) 0.07
N1 201 (78.8%) 199 (72.1%)
Tumor differentiation
Well 16 (6.3%) 58 (21.0%) \ 0.0001
Moderate 160 (62.8%) 160 (58.0%)
Poorly/undifferentiated 73 (28.6%) 56 (20.3%)
Unknown 6 (2.4%) 2 (0.7%)
Margin clearancea
0 mm 63 (26.0%) 67 (25.6%) \ 0.0001
\ 1 mm 64 (26.5%) 38 (14.5%)
C 1 mm 115 (47.5%) 145 (55.3%)
Not reported 0 (0%) 12 (4.6%)
PPPD pylorus-preserving pancreaticoduodenectomy; AJCC American Joint Committee on Cancer
aPatients with an isolated positive pancreatic neck margin not included
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DISCUSSION
Assessment of pathological margin clearance in this
multicenter cohort demonstrated that patients with a mar-
gin clearance of C1 mm have a survival advantage relative
to those with a 0 mm clearance (HR 0.71, p\ 0.01), while
survival was comparable for patients with a margin clear-
ance of\ 1 mm versus 0 mm (HR 0.93, p = 0.60).
Moreover, a similar pattern was found in assessment of
PFS by margin clearance. This finding challenges the tra-
ditional R0/1 definition of margin clearance after PD. In
addition, a positive SMV/PV margin demonstrated a less
negative clinical impact on overall survival than involve-
ment of the SMA margin.
Studies investigating the relationship between margin
clearance and clinical outcome after resected pancreatic
adenocarcinoma have been conflicting. Some studies found
a survival advantage for patients with a margin clearance
above 1 mm and 1.5 mm.21,22 Although a recent, single-
center study from Germany, evaluating 561 patients,
demonstrated a significant survival benefit for patients with
a margin clearance of B1 mm versus 0 mm on unadjusted
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(median survival 27.5 vs. 23.4 months, respectively;
p = 0.01) and multivariate analysis (HR 0.69; 95% CI
0.51–0.94).23 However, a detailed description of the
pathological margin assessment was not provided.
The clinical impact of different involved margins has
also been studied and found significantly decreased sur-
vival in patients with involvement of the SMA or SMV/PV
margins compared to margin-negative resections.24–26
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FIG. 3 Multivariate Cox proportional hazards model assessing hazard of death for the subset of the BID cohort. Model also stratified by type of
adjuvant therapy
TABLE 2 Overall survival stratified by positive margin status
Specific resection
margin
No. of
patients
Median
survival
(mo)
1-year
recurrence rate
(%)
1-year local
recurrence rate (%)
Survival compared with
R0 (log-rank p)
Survival compared with
other R1a (log-rank p)
Negative margins
(C 1 mm clearance)
272 27.2 23.0 10.5 – –
Positive margin (\ 1 mm clearance)
Any positive margin 259 20.1 41.6 27.5 \ 0.001 –
Pancreatic neck
margin
55 19.5 43.3 28.7 0.06 0.66
SMA/uncinated
margin
113 17.5 46.0 32.0 \ 0.0001 0.10
SMV/PV margin
(with or w/o VR)
77 25.7 43.1 32.2 0.30 0.04
SMV/PV margin
(without VR)
49 26.3 33.9 24.2 0.79 0.03
Posterior
retroperitoneal
margin
75 16.7 52.4 38.4 \ 0.01 0.66
Anterior margin 24 20.1 27.9 16.1 0.26 0.75
Proximal
gastric/jejunal
margin
8 13.6b 65.0b 12.5b 0.02b 0.23b
Bile duct margin 5 17.2b 60.0b 60.0b 0.65b 0.76b
R0 survival compared to all patients with a margin clearance of C1 mm, VR venous resection
aOther R1: survival compared to patients with one or more other involved margins (\ 1 mm)
bEstimates may not be reliable due to small numbers
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However, not all studies evaluated the margins separately,
grouping the different margins together either as the medial
margin (SMV/PV and SMA margins) or as transection
margins (SMV/PV, SMA, and pancreatic neck mar-
gins).24,26 The unresolved matter of margin clearance in the
literature may partly be caused by the varying rates of
involvement of each margin, presumably as a result of
heterogeneity in patient selection, surgical technique, and
pathological margin assessment.
This paper provides the first multicenter study of margin
clearance in resected pancreatic cancer and addresses the
pathological challenges of margin assessment after PD in
detail to reach valid conclusions. Follow-up in this study
was relatively long (median follow-up of 49.9 months for
living patients), leading to more accurate 5-year survival
rates. These often are considered as a better reflection of
local recurrence than median survival, due to many patients
with short survival harboring occult metastases.27 Both
centers are academic, high-volume pancreatic centers and
as previously shown differences in adjuvant therapy regi-
mens did not affect survival outcomes.28,29
Survival also was found to be related to the type of
margin involved with better survival for patients with
SMV/PV margin involvement. Clinically, residual disease
would indeed be more likely to be expected after a positive
SMA margin where extrapancreatic soft tissue adjacent to
the SMA is divided. Furthermore, a positive SMV/PV
margin may not necessarily imply that tumor cells are left
behind. If the pancreas was separated intraoperatively from
the SMV/PV without requirement of a venous resection, a
positive margin could ‘‘merely’’ involve tumor cells close
to the pancreatic serosa at the SMV/PV margin. It remains
to be assessed whether margin involvement serves as a
marker for local recurrence, poor tumor biology, or both.
Within the scope of the current study, margin clearance is a
significant prognosticator of recurrence and overall
survival.
There are several limitations, mostly inherent to the
retrospective nature of this study. There may be potential
residual confounding, by not adjusting for CA 19-9 levels,
tumor location, and the number of positive lymph nodes.
Additionally, there were changes in both pathologic
assessment and surgical approach over time. However,
these changes were taken into account to the best of our
ability with contributions of expert pancreatic pathologists
and surgeons to allow for appropriate comparisons. For the
analysis of margin clearance, the different resection mar-
gins were grouped as one; however, the various resection
margins may differently affect outcomes, as evidenced by
previous studies.11,24,26 Furthermore, the distinction
between macroscopically negative (R0/R1) and positive
(R2) margins relies on communication between the sur-
geon and pathologist. While patients with an R2 resection
were excluded from analysis, there may be those with
documented R1 disease who had R2 disease, which could
have resulted in an underestimation of the benefit of R1
resection. Furthermore, certain anatomical boundaries are
considered a surgical limit, for example the SMA margin,
which in the case of tumor infiltration results in an
inevitable macroscopically positive margin.
This work contributes substantially to the current liter-
ature with novel, comprehensible and international data, to
achieve consensus on pathological protocols and defini-
tions. Our subset analysis demonstrates a survival benefit
for patients with a margin clearance of 1–2 mm compared
with 0 mm, which further supports the C 1 mm cutoff for
a margin-negative resection. Lastly, detailed descriptions
of margin assessments were provided for each institution,
something that has mostly been limited or omitted in
clinical studies reported to date.
Margin clearance remains an important variable under
control of the surgeon. Theoretically, margin clearance is
dependent on the extent of the tumor, extent of the surgery,
and the proximity of an absolute anatomic boundary, by
which the surgeon is eventually limited (i.e., either the
SMA or the circumferential surfaces of the pancreas). Our
findings show that patients with a close surgical margin
clearance of\ 1 mm represent a group with similar sur-
vival as those with a margin clearance of 0 mm, whereas
patients with a margin clearance of C 1 mm demonstrated
improved survival.
These results support the C1 mm definition (RCPath)
for R0 resections in pancreatic cancer, which should be
considered for future stratification in randomized, con-
trolled trials. In addition, margin assessment should be
standardized by examining all transection and circumfer-
ential margins, preferably perpendicularly with extensive
sampling to achieve realistic R1 rates, which can be more
easily reconciled with the high rates of local recurrence.18
Finally, in future prospective studies, data collection on the
margin clearance and the specific positive resection margin
should become standard practice to evaluate the effect of
locoregional adjuvant therapies according to margin
clearance and the specific positive resection margins.
Furthermore, as the use of neoadjuvant therapy becomes
more widely adopted, particularly for borderline
resectable disease, the impact of positive resection margins
after neoadjuvant therapy has yet to be evaluated.30
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